证券代码：688343 证券简称：云天励飞 公告编号：2025-045 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 28 日 （二） 股东大会召开的地点：广东省深圳市南山区粤海街道深圳湾科技生态园 10 栋 A 座 3 楼会议室 深圳云天励飞技术股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | 1、出席会议的股东和代理人人数 | 238 | | --- | --- | | 普通股股东人数 | 238 | | 2、出席会议的股东所持有的表决权数量 | 115,500,554 | | 普通股股东所持有表决权数量 | 115,500,554 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 32.3174 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（% ...

Core Viewpoint - The company, Yuntian Lifei, is transitioning to focus entirely on AI inference chips, aiming to become a leader in the domestic AI chip market and drive the large-scale application of artificial intelligence across various scenarios [5][12][20]. Company Background - Founded in 2014 by Chen Ning in Shenzhen, Yuntian Lifei initially focused on AI applications in public security, leveraging facial recognition technology to address social issues like child abduction [2][10]. - The company has evolved over the past nine years, achieving significant milestones in AI applications across consumer, enterprise, and industry sectors, while also being recognized as "Shenzhen's AI first stock" upon its listing on the Sci-Tech Innovation Board [3]. Strategic Shift - In 2025, Yuntian Lifei will fully concentrate on AI inference chips, restructuring its business model from a multi-line approach to a "1+N" model, where "1" represents a unified platform centered on inference chips, and "N" encompasses various business units [11][12]. - The company aims to develop a comprehensive product system for AI inference chips targeting three key markets: edge computing, cloud model inference acceleration, and embodied intelligence [11][12]. Market Potential - The AI inference chip market is viewed as a "blue ocean" with significant growth potential, expected to outpace training chips in the next three to five years [16][20]. - The company anticipates that AI inference chips will become ubiquitous, similar to WiFi routers, serving as core components in smart devices [16][20]. Technological Foundation - Yuntian Lifei has a strong foundation in chip design, having developed the first generation of neural network processors for public security applications, which significantly improved efficiency and reduced costs [10][11]. - The company emphasizes an "algorithm chipification" approach, integrating algorithm requirements with chip architecture to enhance performance and adaptability [19]. Future Outlook - The company is in a critical phase of high investment for growth, with revenue exceeding 900 million yuan in the previous year, reflecting an over 80% year-on-year increase [18]. - Yuntian Lifei is committed to enhancing the efficiency and cost-effectiveness of AI inference chips, aiming to make AI a foundational infrastructure for the fourth industrial revolution [22].

Core Insights - Yuntian Lifei plans to fully focus on AI chips by 2025, leveraging its expertise in neural network processor architecture and commercial chips [1] - The company aims to develop a domestic AI inference chip system characterized by high performance, low cost, and strong adaptability, targeting the AI inference market [1] Company Strategy - Yuntian Lifei will concentrate on three core areas: edge computing, cloud-based large model inference, and embodied intelligence [1] - The company is positioning itself as a leader in China's AI inference chip market, aiming to accelerate the deployment and rapid development of AI across various scenarios [1] Market Outlook - According to MarketsandMarkets, the global AI inference market is projected to reach approximately $106.15 billion (about 737 billion RMB) by 2025, with a compound annual growth rate (CAGR) of 19.2% from 2025 to 2030, potentially reaching around $254.98 billion by 2030 [6]

2025年7月22日，某某采购网发布《关于对深圳云天励飞技术股份有限公司暂停处理公告》。 暂停事由 ：在人员车辆进出营门识别系统项目中涉嫌违规。 供应商：深圳云天励飞技术股份有限公司 违规情况：经调查，深圳云天励飞技术股份有限公司在参加项目（编号：2023-JQ02-W1056）采购活动 中，涉嫌存在违规失信行为。 处理结果：根据军队供应商管理相关规定，自 2025 年 07 月 22 日起暂停其参加全军物资工程服务采购 活动资格。 在暂停期内， 法定代表人陈宁控股或管理的其他企业暂停参加上述范围军队采购活动，授权代表王x暂 停代理其他供应商参加上述范围军队采购活动。 加入"中国IC独角兽联盟"，请点击进入 是说芯语转载，欢迎关注分享 ...

Core Viewpoint - The article discusses the strategic shift of Yuntian Lifei towards AI inference chips, highlighting the growing demand for inference computing power as AI applications proliferate, and the company's recent product launches aimed at this market [2][3][4]. Group 1: AI Inference Market Dynamics - AI is divided into training and inference stages, with inference power demand increasing significantly; IDC reports that cloud inference computing power reached 58.5% in 2022 and is expected to rise to 62.2% by 2026 [2]. - The AI inference chip market is still in a blue ocean phase, with growth expected to outpace the training chip market in the next three to five years, indicating a transition from the training era to the inference era [3][4]. - The demand for AI inference computing is projected to grow over 80% annually, potentially surpassing training as the main driver of data center computing [15]. Group 2: Company Developments and Product Launches - Yuntian Lifei launched the DeepSky X6000 Mesh inference computing card with a computing power of 256 Tops, designed for AI inference applications, supporting 30fps 1080p video decoding [2]. - The company has developed a range of products based on the DeepSky X6000 Mesh card, including various integrated machines with up to 4 PFlops of inference computing power [2][4]. - Yuntian Lifei has successfully transitioned to domestic processes, becoming the first AI chip company to adopt domestic Chiplet technology, and has launched multiple chips under the DeepEdge10 platform [6]. Group 3: Financial Performance and Future Outlook - Yuntian Lifei reported a revenue of over 900 million yuan in 2024, a year-on-year increase of 81.3%, with Q1 2025 revenue reaching 264 million yuan, up 168.23% year-on-year [7]. - The company has signed a significant contract for AI training and inference heterogeneous computing services, expected to contribute approximately 1.6 billion yuan in revenue over three years [7]. - The CEO emphasizes the importance of AI inference chips in driving the large-scale application of AI technologies in various sectors, predicting a transformative impact on electronic products in the next five years [8][9].

Core Viewpoint - The announcement details the first vesting results of the 2023 restricted stock incentive plan for Shenzhen Yuntian Lifei Technology Co., Ltd, including the number of shares vested and the upcoming listing date for these shares [1][6]. Summary by Sections Incentive Plan Overview - The total number of shares listed for circulation under the incentive plan is 3,692,940 shares, with a listing date set for July 29, 2025 [1][6]. - The plan includes both the initial grant and reserved grants, with the first vesting period now completed [1][4]. Decision-Making Process - The decision-making process for the stock vesting involved multiple meetings of the board and supervisory committee, which reviewed and approved various related proposals [2][3][4]. - Independent directors provided opinions affirming that the conditions for granting the shares had been met [3][4]. Vesting Details - A total of 182 individuals received shares from the initial grant, while 2 individuals received shares from the reserved grant [5]. - The actual number of shares vested for key personnel includes: - 邓浩然: 40,000 shares (50% of granted) - 李爱军: 5,000 shares (50% of granted) - 王磊: 6,000 shares (30% of granted) - 郑文先: 5,000 shares (50% of granted) - Total for other key personnel: 367,924 shares (49% of granted) [4][5]. Stock Source and Listing - The shares vested are sourced from the company's directed issuance of A-shares to the incentive recipients [5]. - The total share capital of the company will increase from 355,133,720 shares to 358,826,660 shares following this vesting [6][9]. Financial Impact - The company reported a net loss of 85,641,998.79 yuan for Q1 2025, with a basic earnings per share of -0.24 yuan. The new shares will slightly dilute earnings per share but are not expected to significantly impact the financial results [9].

证券代码：688343 证券简称：云天励飞 公告编号：2025-044 深圳云天励飞技术股份有限公司 关于 2023 年限制性股票激励计划首次授予部分 及预留授予部分（第一批次）第一个归属期 归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 3,692,940股。 本次股票上市流通总数为3,692,940股。 本次股票上市流通日期为2025 年 7 月 29 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司相关业务规定，深圳云天励飞技术股份有限公司（以下简称"公 司"）于近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更 登记证明》，公司完成了 2023 年限制性股票激励计划（以下简称"本激励计划"） 首次授予部分及预留授予部分（第一批次）第一个归属期的股份归属登记工作。 现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 6、2023 年 12 月 ...

Core Insights - The Sci-Tech Innovation Board (STAR Market) has become a significant platform for technology innovation and capital market reform in China, celebrating its sixth anniversary with 589 listed companies as of July 22, 2025 [1] Group 1: STAR Market Development - The STAR Market has continuously promoted institutional innovation and industrial upgrading, attracting global attention as a hub for "hard technology" enterprises [1] - Since its launch on July 22, 2019, the STAR Market has supported the listing of 25 initial companies, marking the beginning of its journey [1] Group 2: Company Perspectives - Haiguang Information has made significant progress in governance, innovation, competition, and operations, focusing on high-end processor business and increasing R&D investment [2] - The company has independently developed multiple generations of general-purpose CPUs and AI accelerators, achieving a leading market share in domestic high-end computing and intelligent computing sectors [2] - Baili Tianheng has benefited from the STAR Market's support for high-quality development of unprofitable enterprises, focusing on innovative drug development in oncology [4] - The company has initiated a fundraising plan for innovative drug R&D, aiming to expand its product pipeline and commercialize more products [4] - Tuojing Technology has experienced accelerated growth post-listing, achieving profitability in its first year and expanding its production scale in semiconductor equipment [6] - Zhongkong Technology has leveraged capital market support for R&D in AI and robotics, enhancing its governance structure and operational efficiency [7] - Zexin Pharmaceutical has successfully launched three new drug products and established a competitive product pipeline, benefiting from STAR Market policies [9] - Hehui Optoelectronics has recognized the STAR Market's reforms as a significant boost to its innovation capabilities and market adaptability [10] Group 3: Policy Impact - The introduction of the "1+6" policy measures aims to enhance the STAR Market's support for technology innovation enterprises, addressing core pain points and growth patterns [10][12] - The establishment of the Sci-Tech Growth Layer provides a dedicated capital channel for high-potential, non-profitable enterprises, facilitating their transition through the "valley of death" [11] - The reforms emphasize long-term value assessment based on technological advancement and market potential, rather than short-term profitability [12] - The STAR Market is expected to cultivate globally competitive technology leaders, contributing to high-quality economic development in China [12][14]

Core Points - The stock price of Yuntian Lifei (688343) closed at 51.55 yuan on July 18, 2025, with a slight decrease of 0.21% [1] - The company reported a total revenue of 264 million yuan for Q1 2025, representing a year-on-year growth of 168.23% [1] - The net profit attributable to shareholders was 85.64 million yuan, showing a year-on-year increase of 37.86% [1] - The company has a current ratio of 5.468 and a quick ratio of 5.060, indicating strong liquidity [1] - The debt-to-asset ratio stands at 32.59%, reflecting a moderate level of financial leverage [1] Investment and Business Activities - Yuntian Lifei has made investments in 31 companies and participated in 269 bidding projects [2] - The company holds 415 trademark registrations and 1,801 patents, showcasing its strong intellectual property portfolio [2] - Additionally, Yuntian Lifei has obtained 37 administrative licenses, indicating compliance with regulatory requirements [2]

Core Viewpoint - Shenzhen Yuntian Lifi Technology Co., Ltd. is planning to issue H shares and list on the main board of the Hong Kong Stock Exchange to enhance its competitiveness and international brand image while diversifying its financing channels [9][10][11]. Group 1: Meeting Procedures - The meeting will be conducted using a combination of on-site and online voting methods [5]. - Attendees must arrive 30 minutes before the meeting to sign in and present identification [2]. - The meeting will follow a specific agenda for reviewing and voting on proposals [4][5]. Group 2: Proposals for H Share Issuance - Proposal 1: The company plans to issue H shares and list them on the Hong Kong Stock Exchange, with the shares being ordinary shares with a par value of RMB 1.00 each [10][11]. - Proposal 2: The issuance will include a public offering in Hong Kong and an international placement, with the total number of H shares not exceeding 15% of the company's total share capital post-issuance [11][12]. - Proposal 3: The company will seek authorization from the shareholders to handle all matters related to the H share issuance, including determining the issuance scale and pricing [19][20]. Group 3: Governance Changes - The company proposes to abolish the supervisory board, transferring its powers to the audit committee of the board of directors, and will revise its articles of association accordingly [6][7]. - The internal governance rules will also be updated to reflect the changes in the supervisory structure [7][8]. Group 4: Use of Proceeds - The funds raised from the H share issuance will be allocated for R&D of AI inference chips, expanding product applications, and enhancing global market presence [17]. - The board will have the authority to adjust the use of proceeds based on regulatory feedback and operational needs [17]. Group 5: Legal and Regulatory Compliance - The company will ensure compliance with all relevant laws and regulations during the H share issuance process, including those from the China Securities Regulatory Commission and the Hong Kong Stock Exchange [9][10][25]. - Legal opinions will be provided by the appointed law firm to ensure the legality of the proceedings [4][5].